Clinical Trial

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the interaction of oral HRS-9813 capsules with pirfenidone and nintedanib on the pharmacokinetics of healthy subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Status change: Not Yet Recruiting → Recruiting 2026-04-23
Trial Details
NCT Number NCT07229716
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Pulmonary Fibrosis
Enrollment 20 participants
Start Date 2026-04-04
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-27